$MRSH

South Martin sold $1.3M of MRSH

South Martin (Chief Client Officer) sold 7,100 shares of MARSH & MCLENNAN COMPANIES, INC. (MRSH) at $189.99 ($1.35M total) on 2026-07-28.

Original reporting
SEC EDGAR · South Martin
Published Jul 29, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 6:07 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MRSH
Neutral
high confidence
Mentioned
$MRSH
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MRSHNeutralLow
01

Why it matters

The newest fact is the reported open-market sale size, price, and post-transaction holdings by the Chief Client Officer.

02

Market read

Traders may note insider selling, but the disclosure alone does not provide a new fundamental catalyst.

03

What to watch

The article notes no 10b5-1 plan; however, it still lacks context on motivations, compensation timing, or whether other insiders are buying.

Relevance 6/10Novelty 3/10Timing: Filed 2026-07-29, covering a sale executed 2026-07-28.

Background

The article is a SEC Form 4 insider transaction disclosure for Marsh & McLennan (MRSH).

Company-level read

Ticker impact

$MRSHNeutralHigh confidence
Context

Marsh & McLennan insider South Martin sold 7,100 shares on 2026-07-28 at $189.9925, totaling about $1.35M.

Expected impact

Likely minimal near-term impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing is an insider sale (not a buy), and the text provides no accompanying company-specific catalyst such as guidance, contracts, or litigation.

Market effects

No clear sector read-through from a single insider sale disclosure.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-planned liquidity needs, so the signal may be overstated.

Key entities

  • Marsh & McLennan Companies, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • South Martin

    Chief Client Officer who sold shares via open-market sale.

Related articles

$MRSHMed

Marsh & McLennan Companies Q2 Earnings Call Highlights

Marsh & McLennan (NYSE:MRSH) reported Q2 results and discussed market conditions on its earnings call. Consulting revenue rose 10% to $2.6B, with adjusted operating income up 11% to $533M. Mercer revenue was $1.6B. Marsh Global Insurance Market Index showed primary commercial rates down 6% in Q2. The company ended with $20.6B debt and $1.7B cash, and expects $5.5B capital deployment in 2026.

$MRSHMed

Marsh (NYSE:MRSH) Exceeds Q2 CY2026 Expectations

Marsh (NYSE:MRSH) reported Q2 CY2026 results. Revenue rose 6.2% year on year to $7.40 billion, exceeding Wall Street’s estimate by 1.8%, and non-GAAP EPS was $2.96, 2.3% above consensus. Adjusted operating margin was 26.9%. Analysts expect revenue growth of 4.2% and full-year EPS to rise from $10.22 to $10.90.

$MRSHMed

MARSH & MCLENNAN COMPANIES, INC. (MRSH): Results of Operations and Financial Condition

MARSH & MCLENNAN COMPANIES, INC. (MRSH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 mmc2q2026ex991newsrelease.htm PRESS RELEASE JUNE 30, 2026 Document Marsh 212 345 5000 www.corporate.marsh.com News release Exhibit 99.1 Marsh reports second quarter 2026 results • Revenue Growth of 6%; Underlying Revenue Growth of 5% • GAAP Operating Income Increases 4%

$MRSHHighAI 9/10

Marsh & McLennan Companies (NYSE:MRSH) Stock Price Down 13.1% After Analyst Downgrade

Marsh & McLennan (NYSE:MRSH) fell 13.1% mid-day Wednesday after Piper Sandler cut its price target to $182 from $190 and kept a neutral rating. Shares traded as low as $180.97 and last at $160.70, after closing $185.00; volume rose to 3.04M. The article also cites recent analyst target changes and April 16 quarterly results: $3.29 EPS vs $3.21 consensus on $7.30B revenue.